Virtual eye model system for personalised refractive surgery treatment
The incidence of myopia is predicted to rise from 28% of the global population in 2010 to almost 50% in 2050. Factors such as population aging and increase of hours spent in front of screens are driving the increase in global eye...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto VEMoS
Duración del proyecto: 46 meses
Fecha Inicio: 2019-11-05
Fecha Fin: 2023-09-30
Líder del proyecto
VALCASADO SA
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The incidence of myopia is predicted to rise from 28% of the global population in 2010 to almost 50% in 2050. Factors such as population aging and increase of hours spent in front of screens are driving the increase in global eye deficits. Vision impairments reduce the quality of life, affect economic and educational opportunities and increase the risk of death. This is particularly important for vulnerable groups such as elderly, children, workers and drivers. Overall, WHO reported that uncorrected vision was responsible for €241bn of productivity loss per year worldwide.
Our innovative Virtual Eye Model System (VEMoS) is based on patented revolutionary ophthalmic diagnostic devices (CSO’s MS-39 tomographer/topographer and the unique open-field aberrometer), as well as on innovative simulation software developed by Vissum. Overall, our innovation provides personalised clinical-decision support based on each patient’s eye measurements and neural network simulations of post-surgery outcomes, improving surgery success and patient satisfaction rates.
By combining CSO’s ophthalmic high-tech hardware design, manufacturing and commercialisation skills with Vissum’s refractive surgery and software development and independent clinical testing by CHUC and AUH, this project is expected to bring economic, social and health impacts, including progress towards achieving the EC action plan on personalised medicine ICPerMed. Our goal is to mature, scale-up and demonstrate the production of the VEMoS system, targeting ophthalmology clinics as clients, and with the aim to standardise refractive surgery decision making and revolutionise the refractive surgery field with personalised treatments.
A successful VEMoS project will allow us to create measurable impacts on our companies, quantified as accumulated revenue of €145.3m in five years (2022-2026), equal to accumulated operating profit of €58.2m, creating 60 full time employments, and generating €37m in reduced customer costs.